125 related articles for article (PubMed ID: 12881399)
21. Androgen receptor in salivary gland carcinoma: A review of an old marker as a possible new target.
Yeoh CC; Dabab N; Rigby E; Chhikara R; Akaev I; Gomez RS; Fonseca F; Brennan PA; Rahimi S
J Oral Pathol Med; 2018 Aug; 47(7):691-695. PubMed ID: 29863801
[TBL] [Abstract][Full Text] [Related]
22. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity.
Kawata H; Ishikura N; Watanabe M; Nishimoto A; Tsunenari T; Aoki Y
Prostate; 2010 May; 70(7):745-54. PubMed ID: 20058237
[TBL] [Abstract][Full Text] [Related]
23. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
24. The successful treatment of metastatic androgen receptor-positive tumours of parotid origin with androgen receptor blockade and immunotherapy.
Dalgleish AG; Di Palma S; Nathan K; Powell B; Patel N; Fusi A
Eur J Cancer; 2019 May; 113():14-18. PubMed ID: 30954882
[No Abstract] [Full Text] [Related]
25. [Exulcerating cystadenolymphoma of the parotid gland. A case report].
Ellies M; Kunze E; Laskawi R
Laryngorhinootologie; 1995 Apr; 74(4):245-7. PubMed ID: 7772225
[TBL] [Abstract][Full Text] [Related]
26. Androgen deprivation for prostatic carcinoma: a rationale for choosing components.
Fourcade RO; Chatelain C
Int J Urol; 1998 Jul; 5(4):303-11. PubMed ID: 9712436
[TBL] [Abstract][Full Text] [Related]
27. Primary signet-ring cell/histiocytoid carcinoma of the eyelid expressing androgen receptors and treated with bicalutamide.
Sakamoto K; Ito T; Tanioka F; Fukamizu H; Tokura Y
J Dermatol; 2017 Sep; 44(9):e230-e231. PubMed ID: 28543368
[No Abstract] [Full Text] [Related]
28. Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study.
Montironi R; Diamanti L; Santinelli A; Galetti-Prayer T; Zattoni F; Selvaggi FP; Pagano F; Bono AV
Pathol Res Pract; 1999; 195(4):201-8. PubMed ID: 10337657
[TBL] [Abstract][Full Text] [Related]
29. Cancer of the parotid gland: role of 7th nerve preservation.
Spiro JD; Spiro RH
World J Surg; 2003 Jul; 27(7):863-7. PubMed ID: 14509520
[TBL] [Abstract][Full Text] [Related]
30. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission.
Levine D; Park K; Juretzka M; Esch J; Hensley M; Aghajanian C; Lewin S; Konner J; Derosa F; Spriggs D; Iasonos A; Sabbatini P
Cancer; 2007 Dec; 110(11):2448-56. PubMed ID: 17918264
[TBL] [Abstract][Full Text] [Related]
31. Intermittent, low-dose, antiandrogen monotherapy as an alternative therapeutic option for patients with positive surgical margins after radical prostatectomy.
Choi KH; Lee SR; Hong YK; Park DS
Asian J Androl; 2018; 20(3):270-275. PubMed ID: 29271399
[TBL] [Abstract][Full Text] [Related]
32. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
Rigatti P; Scattoni V
Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
[No Abstract] [Full Text] [Related]
33. [Bicalutamide].
Taéron C
Rev Infirm; 2010 Mar; (158):47-9. PubMed ID: 20383962
[No Abstract] [Full Text] [Related]
34. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299.
Eggener S
Urol Oncol; 2014 Aug; 32(6):936-7. PubMed ID: 25087673
[TBL] [Abstract][Full Text] [Related]
35. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr., University of Michigan, Division of Hematology/Oncology, 1500 E Medical Center Dr., 7314 CC, Ann Arbor, MI. N Engl J Med 2013;368(14):1314-25.
Trump DL
Urol Oncol; 2013 Nov; 31(8):1847. PubMed ID: 24210086
[TBL] [Abstract][Full Text] [Related]
36. Agonist and antagonist activities of hydroxyflutamide and Casodex relate to androgen receptor stabilization.
Kemppainen JA; Wilson EM
Urology; 1996 Jul; 48(1):157-63. PubMed ID: 8693644
[No Abstract] [Full Text] [Related]
37. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
Rusakov IG; Alekseev BIa
Urologiia; 2002; (5):23-6. PubMed ID: 12402771
[No Abstract] [Full Text] [Related]
38. The importance of postoperative radiotherapy against polymorphous low-grade adenocarcinoma of the parotid gland: case report and review of the literature.
Uemaetomari I; Tabuchi K; Tobita T; Tsuji S; Wada T; Kamma H; Hara A
Tohoku J Exp Med; 2007 Mar; 211(3):297-302. PubMed ID: 17347556
[TBL] [Abstract][Full Text] [Related]
39. Superfacial parotidectomy for pleomorphic parotid adenomas.
Hawe MJ; Bell DM
Clin Oncol; 1982; 8(3):207-13. PubMed ID: 7140047
[TBL] [Abstract][Full Text] [Related]
40. Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal.
Kundranda MN; Muslimani A; Daw HA; Spiro TP
Clin Genitourin Cancer; 2007 Sep; 5(6):401-2. PubMed ID: 17956714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
